Cargando…

Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED)

BACKGROUND: Dry eye disease (DED) affects millions of people worldwide. There are a variety of new treatments beyond traditional therapies such as preservative free artificial tears. Here, we conduct a survey to identify the most common treatments used among specialists and assess their interest in...

Descripción completa

Detalles Bibliográficos
Autores principales: Sy, Aileen, O’Brien, Kieran S., Liu, Margaret P., Cuddapah, Puja A., Acharya, Nisha R., Lietman, Thomas M., Rose-Nussbaumer, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604775/
https://www.ncbi.nlm.nih.gov/pubmed/26462481
http://dx.doi.org/10.1186/s12886-015-0122-z
_version_ 1782395104399458304
author Sy, Aileen
O’Brien, Kieran S.
Liu, Margaret P.
Cuddapah, Puja A.
Acharya, Nisha R.
Lietman, Thomas M.
Rose-Nussbaumer, Jennifer
author_facet Sy, Aileen
O’Brien, Kieran S.
Liu, Margaret P.
Cuddapah, Puja A.
Acharya, Nisha R.
Lietman, Thomas M.
Rose-Nussbaumer, Jennifer
author_sort Sy, Aileen
collection PubMed
description BACKGROUND: Dry eye disease (DED) affects millions of people worldwide. There are a variety of new treatments beyond traditional therapies such as preservative free artificial tears. Here, we conduct a survey to identify the most common treatments used among specialists and assess their interest in newer therapies. METHODS: An international survey was distributed to dry eye researchers and expert practitioners via an internet survey. The survey data collected were analyzed with descriptive statistics. RESULTS: One hundred and fifteen respondents completed the survey; of these, 66 % were cornea specialists. The most commonly prescribed topical treatments included cyclosporine A (CSA) 0.05 % (71/104, 68 %), fluorometholone (FML) 0.1 % (59/99, 60 %), loteprednol etabonate 0.5 % (50/99, 51 %), and autologous serum eye drops (ASD; 48/97, 49 %). The most commonly prescribed non-topical medications included essential fatty acid supplements (72/104, 69 %), low-dose doxycycline (oral; 61/100, 61 %), and flaxseed supplements (32/96, 33 %) as well as punctal plugs (76/102, 75 %). Respondents reported treatment with topical corticosteroids for 2 to 8 weeks (46/86, 53 %), followed by less than 2 weeks (24/86, 28 %) and with topical CSA between 2 to 8 weeks (45/85, 53 %) followed by 2 to 6 months (24/85, 28 %). The top three signs and symptoms reported to indicate treatment response were, in order, fluorescein staining of the cornea, reduction in foreign body sensation, and reduction in burning sensation. CONCLUSION: This survey offers insight into current expert opinion in the treatment of DED. The results of this survey are hypothesis generating and will aid in the design of future clinical studies.
format Online
Article
Text
id pubmed-4604775
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46047752015-10-15 Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED) Sy, Aileen O’Brien, Kieran S. Liu, Margaret P. Cuddapah, Puja A. Acharya, Nisha R. Lietman, Thomas M. Rose-Nussbaumer, Jennifer BMC Ophthalmol Research Article BACKGROUND: Dry eye disease (DED) affects millions of people worldwide. There are a variety of new treatments beyond traditional therapies such as preservative free artificial tears. Here, we conduct a survey to identify the most common treatments used among specialists and assess their interest in newer therapies. METHODS: An international survey was distributed to dry eye researchers and expert practitioners via an internet survey. The survey data collected were analyzed with descriptive statistics. RESULTS: One hundred and fifteen respondents completed the survey; of these, 66 % were cornea specialists. The most commonly prescribed topical treatments included cyclosporine A (CSA) 0.05 % (71/104, 68 %), fluorometholone (FML) 0.1 % (59/99, 60 %), loteprednol etabonate 0.5 % (50/99, 51 %), and autologous serum eye drops (ASD; 48/97, 49 %). The most commonly prescribed non-topical medications included essential fatty acid supplements (72/104, 69 %), low-dose doxycycline (oral; 61/100, 61 %), and flaxseed supplements (32/96, 33 %) as well as punctal plugs (76/102, 75 %). Respondents reported treatment with topical corticosteroids for 2 to 8 weeks (46/86, 53 %), followed by less than 2 weeks (24/86, 28 %) and with topical CSA between 2 to 8 weeks (45/85, 53 %) followed by 2 to 6 months (24/85, 28 %). The top three signs and symptoms reported to indicate treatment response were, in order, fluorescein staining of the cornea, reduction in foreign body sensation, and reduction in burning sensation. CONCLUSION: This survey offers insight into current expert opinion in the treatment of DED. The results of this survey are hypothesis generating and will aid in the design of future clinical studies. BioMed Central 2015-10-13 /pmc/articles/PMC4604775/ /pubmed/26462481 http://dx.doi.org/10.1186/s12886-015-0122-z Text en © Sy et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Sy, Aileen
O’Brien, Kieran S.
Liu, Margaret P.
Cuddapah, Puja A.
Acharya, Nisha R.
Lietman, Thomas M.
Rose-Nussbaumer, Jennifer
Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED)
title Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED)
title_full Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED)
title_fullStr Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED)
title_full_unstemmed Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED)
title_short Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED)
title_sort expert opinion in the management of aqueous deficient dry eye disease (ded)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604775/
https://www.ncbi.nlm.nih.gov/pubmed/26462481
http://dx.doi.org/10.1186/s12886-015-0122-z
work_keys_str_mv AT syaileen expertopinioninthemanagementofaqueousdeficientdryeyediseaseded
AT obrienkierans expertopinioninthemanagementofaqueousdeficientdryeyediseaseded
AT liumargaretp expertopinioninthemanagementofaqueousdeficientdryeyediseaseded
AT cuddapahpujaa expertopinioninthemanagementofaqueousdeficientdryeyediseaseded
AT acharyanishar expertopinioninthemanagementofaqueousdeficientdryeyediseaseded
AT lietmanthomasm expertopinioninthemanagementofaqueousdeficientdryeyediseaseded
AT rosenussbaumerjennifer expertopinioninthemanagementofaqueousdeficientdryeyediseaseded